Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Anakinra
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2020
Details:
First study to report use of anakinra to treat COVID-19 infection found that high-dose anakinra was safe and was associated with a 90% survival rate and reduced respiratory symptoms associated with severe COVID-19 infection.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Anakinra
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2020
Details:
Swedish Orphan Biovitrum AB will begin a short-term clinical study to evaluate the efficacy and safety of anakinra and emapalumab in the treatment of hyper-inflammatory syndrome in COVID-19 disease.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
